



CSL Research Acceleration Initiative

Applications close 24th February 2026

WHY COLLABORATE WITH CSL?



Funding of up to \$400,000 USD over 2 years



Access global capabilities and expertise
CSL scientific champion assigned to provide industry guidance and help you leverage our global capabilities



Publish with CSL
270+ publications with our collaborators since 2020



Accelerate Translation of your research into new therapies

CSL is a leading global biotech company delivering innovative therapies to help people with life-threatening conditions live full lives.

The CSL **Research Acceleration Initiative** supports early-stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.

Successful applicants can receive up to **\$400,000 USD in non-dilutive funding** over 2 years to advance their innovative programs.

Interested researchers are invited to:

- **Attend an information webinar (choose one of two sessions)**

Thursday, 29 January 11:00AM EST – [Click to join](#)

Thursday, 5 February 1:00PM EST – [Click to join](#)

- **Submit enquiries, expressions of interest and requests for application instructions to:**

Name:

Email:

- **Submit** a non-confidential, 500-word abstract via the CSL online application portal by **24th February 2026**.

The 2026 Research Acceleration Initiative will focus on research proposals that align with a CSL **Therapeutic Area**. Please see over page for specific **Focus Areas**.

Therapeutic Areas



Immunoglobulins



Hematology



Cardio-Renal



Transplant & Immunology

CSL Research Acceleration Initiative

Focus Areas



CSL is seeking applications that align with a CSL Therapeutic Area in the following Focus Areas

Transplant & Immunology Novel first in class targets and drug concepts to treat immune-mediated diseases e.g. - Strategies for targeting pathogenic T cell subsets - Strategies for targeting disease-driving chemokine receptors - Multi-specific approaches that enable multiple cell types/ pathways to be targeted to treat complex immune-mediated diseases - Strategies for targeting stromal cells, senescence or inflammaging Indication focus - Chronic immune mediated rheumatologic and dermatologic diseases - Rare neuro-immune disorders	Cardiovascular & Renal Genetic rare renal diseases Novel targets or therapeutic candidates for polycystic kidney disease autosomal dominant tubulointerstitial kidney disease and Alport syndrome Autoimmune-mediated rare renal diseases Novel targets or therapeutic candidates for autoimmune-mediated rare glomerular diseases and ANCA-associated vasculitis Rare cardiovascular diseases Novel targets or therapeutic candidates for inflammatory, autoimmune or genetic cardiomyopathies Novel targets or therapeutic candidates for immune checkpoint inhibitor-induced myocarditis	Hematology Acute hemorrhage control and Patient Blood Management (PBM) - Pro-hemostatic therapies for anti-platelet agent-associated hemorrhage and intracerebral hemorrhage - Treatments for targeting and preventing hyperfibrinolysis- and vascular malformations-associated bleeding Transformative therapies for Hemophilia A - Next generation non-AAV-based gene therapy - Oral protein or nucleic acid-based treatments Iron metabolism - Novel treatments for iron deficiency and anemia - Novel formulation approaches: oral & intramuscular iron supplementation - Novel therapies to treat iron overload conditions - Disease modifying therapies for myeloproliferative neoplasms including polycythemia vera , essential thrombocythemia, myelofibrosis and myelodysplastic syndrome Acute thrombotic conditions Novel therapies applicable to a broad spectrum of acute thrombotic diseases including microangiopathies (TMAs; pan-treatment)
Immunoglobulins Patient Experience - High concentration/low volume formulation technologies - Improve ease of administration and decrease administration time for plasma-derived products - Technologies that enable novel routes of administration for plasma-derived products Novel Therapies for - Primary and Secondary Immunodeficiency Disorders - Alpha 1 Antitrypsin Deficiency Optimization of human-derived Ig products - Technologies that can optimize, supplement or replace human-derived products		
Oral Delivery Technologies enabling systemic oral delivery of biologics (e.g. antibodies and other large proteins)		